To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Recruiting · NCT06756269 · Registry updated 2025-12-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years | DNA Virus Infections, Disease Attributes, Genital Diseases, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, Urogenital Diseases, anogenital human papillomavirus infection, common wart, human papilloma virus infection, infectious disease, sexually transmitted disease, skin disorder, skin disorder caused by infection, viral infectious disease, viral sexually transmitted disease | Recruiting | Phase 2 | 2025-12-17 | NCT06756269 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Bovax Biotechnology Co., Ltd. | 4 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention | Nanning | China | 7 |